Abstract:Objective To assess the efficacy and safety of oxaliplatin combined with capecitabine in preoperative concurrent chemoradiotherapy for high-risk locally advanced rectal cancer. Methods We retrospectively screened patients with locally advanced adenocarcinoma of the rectum (T3 or T4 with any N, or any T with node positivity) in Peking University Cancer Hospital and Institute from March 2018 to February 2019. The eligible patients had at least one of the following high-risk factors: very low cancer, clinical T4b, mesorectal fascia involvement, positive extramural venous invasion, and lateral lymph node involvement. The patients received preoperative intensity-modulated radiotherapy (95% planning gross tumor volume 50.6 Gy/95% planning target volume 41.8 Gy/22 f/30 d, a single fraction per day) with concurrent oxaliplatin 85 mg/m2 at d1 per two weeks and capecitabine 825 mg/m2 twice daily for 5 days per week. The primary outcome was complete response (clinical and pathologic complete response) rate. Secondary outcomes included adverse reactions, postoperative complications, R0 resection rate, anus-preserving operation rate, down-staging rate, tumor regression grade (TRG), local recurrence rate, and distant metastasis rate. Results In total, 63 patients were included in the analysis. Among them, 63 (100%) completed all radiotherapy doses, and 50 (79.37%) received all three cycles of chemotherapy. There were no cases of grade 4 adverse reactions, and grade 3 adverse reactions occurred in 5 (7.94%) cases. Of 46 patients who underwent surgery, the R0 resection rate was 100%, and the anus-preserving operation rate was 73.91% (36/46). The complete response rate was 34.92% (22/63). The T and N down-staging rates were 82.61% (38/46) and 95.65% (44/46), respectively. The percentages of cases with TRG 0, 1, and 2 were 30.43% (14/46), 45.65% (21/46), and 23.91% (11/46), respectively. Postoperative complications occurred in 6 cases, all of which were relieved by conservative treatments. The median follow-up time was 7.2 months. There was no death or local recurrence during follow-up, and 4 (6.35%, 4/63) cases had distant metastasis. Conclusion For patients with high-risk locally advanced rectal cancer, oxaliplatin combined with capecitabine in concurrent chemoradiotherapy has good short-term efficacy and acceptable adverse reactions, which may be a better candidate for neoadjuvant therapy. Key words: Rectal neoplasms; Antineoplastic combined chemotherapy protocols; Oxaliplatin; Capecitabine

The application of neoadjuvant chemotherapy oxaliplatin plus capecitabine in mid-low rectal carcinoma

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Neoadjuvant Chemotherapy with Xelox Regimen for Locally Advanced Operable Colon Cancer Patients: A Prospective Phase Ii Trial (Nct02415829)

Application of oxaliplatin combined with capecitabine in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer

Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer

Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine for Pathological Stage N2 Rectal Cancer.

Effectiveness and safety of neoadjuvant apatinib in combination with capecitabine and oxaliplatin for the therapy of locally advanced colorectal cancer: A retrospective study

The Effect of Oxaliplatin Plus Capecitabine in Combination with Radiation for Locally Advanced Lower or Middle Sited Rectal Carcinoma

A Phase II Trial of Xeloda and Oxaliplatin (XELOX) Neo-Adjuvant Chemotherapy Followed by Surgery for Advanced Gastric Cancer Patients with Para-Aortic Lymph Node Metastasis

Phase Ii Trial Of Neoadjuvant Chemoradiation With Concomitant Boost Followed By A Coycle Of Xelox In Locally Advanced Rectal Cancer

Adjuvant Chemotherapy Containing Oxaliplatin Without Radiotherapy to Improve Survival of Local Advanced Low and Middle Rectal Cancer

Efficacy and Safety of Capecitabine Plus Oxaliplatin (xelox) As the Perioperative Treatment of Patients with Potentially Resectable Liver-Only Metastases from Colorectal Cancer: A Single Arm, Open-Label, Multicenter Phase Ii Trial (ml22298; Nct00997685).

Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy (NEO-CLASSIC).

Neoadjuvant Chemotherapy with Capecitabine Combined with Oxaliplatin for Mid-Low Locally Advanced Rectal Cancer with Negative Mesorectal Fascia: Long-term Outcomes of a Prospective Trial (PKUCH-R03 Trial).

Efficacy of Preoperative Chemotherapy Regimens in Patients with Initially Unresectable Locally Advanced Gastric Adenocarcinoma: Capecitabine and Oxaliplatin (XELOX) or with Epirubicin (EOX).